


Curriculum Vitae

Name	Hyo Song Kim	
Current Position & Affiliation	Associate Professor, Yonsei University	
Country	Korea, Republic Of	

Educational Background

2008 Mar - 2013 Feb PhD, School of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of, Supervisor(s): Won Ki Kang, MD, PhD
 2006 Mar - 2008 Feb MMS, School of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of, Supervisor(s): Won Ki Kang, MD, PhD
 1996 Mar - 2002 Feb MD, School of Medicine Gyeongsang National University, Jinju, Korea

Professional Experience

2008 Mar - 2009 Feb Clinical fellowship, Hematology/Oncology, Division of Hematology/Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Republic Of, Supervisor(s): Won Ki Kang, MD, PhD
 2007 June - 2007 July Visiting Residency, Division of Medical Oncology, National Cancer Center, Singapore, Supervisor(s): Soon Thye Lim, MD, PhD
 2004 Mar - 2008 Feb Residency, Internal Medicine, Hematology/Oncology Subspecialty, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of
 2003 Mar - 2003 Dec ESL course, English Language School in Vancouver, Canada
 2002 Mar - 2003 Feb Internship program, Medicine (rotational), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Republic Of

Professional Organizations

2008 Jan - present	Active member, Korean Cancer Study Group
2008 Jan - present	Active member, Korean Association for Clinical Oncology
2008 Jan - present	Active member, Korean Cancer Society
2009 May - present	International Member, American Society of Clinical Oncology
2009 May - present	Associate Member, American Association of Cancer Research

Main Scientific Publications

1. Kim KH, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim do H, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer, *Cancer Chemother Pharmacol*
2. Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. *Cancer Chemother Pharmacol*. 2009 May
3. Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM.
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. *Cancer Chemother Pharmacol*. 2008 Jun
4. "Kim HS, Nam CM, Jang SY, Choi SK, Han M, Kim S, Moneta MV, Lee SY, Cho JM, Novick D, Rha SY. *Cancer Res Treat*. 2019 Oct;51(4):1380-1391. doi: 10.4143/crt.2018.476. Epub 2019 Feb 18. Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
5. "Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S. *Oncotarget*. 2017 Jun
Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
6. "Kim HS, Koom WS, Baek SE, Kim HI, Jung M, Beom SH, Kang B, Kim H, Chang JS, Choi YY, Son T, Cheong JH, Noh SH, Kim EH, Park JC, Shin SK, Lee SK, Lee YC, Shin SJ, Chung H, Jung I, Chung HC, Lim JS, Hyung WJ, Rha SY. *Radiother Oncol*. 2019
Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer